Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report) recently announced positive interim results from a phase II study on ALN-TTR02. ALN-TTR02 is a ribo nucleic acid interference (RNAi) therapeutic targeting the transthyretin (TTR) gene for treating TTR-mediated amyloidosis (ATTR).

Alnylam is evaluating the safety and tolerability of ALN-TTR02 (0.01 to 0.30 mg/kg doses) in the phase II study. Alnylam will also assess clinical activity based on serial measurement of circulating serum levels of wild-type and mutant TTR. The company is conducting the study in 10 different countries including Portugal, France, Sweden, Germany, Spain, Brazil and the US.

A rapid, dose-dependent, and durable knockdown of serum TTR levels was observed in the first 19 patients enrolled and analyzed in this study. The study also revealed that several doses of ALN-TTR02 were generally safe and well tolerated.

Meanwhile, Alnylam plans to initiate an open-label extension (OLE) study on ALN-TTR02 in patients from the phase II study shortly. The company will evaluate the neuropathy impairment score in these patients in the extension study along with other clinical objectives.

Alnylam has plans to present data from this study in 2014. Moreover, the company has plans to initiate a phase III pivotal study on ALN-TTR02 in patients suffering from familial amyloidotic polyneuropathy (FAP) by the end of this year.

We note that Alnylam has a development and commercialization agreement with Sanofi (SNY - Analyst Report) for Alnylam’s RNAi therapeutics, which include ALN-TTR02 and ALN-TTRsc. The agreement is for the development and commercialization of these candidates in Japan and the broader Asian-Pacific region. Alnylam intends to develop and commercialize the ALN-TTR program in other countries as well.

We are encouraged by the company’s progress with its lead pipeline candidate, ALN-TTR02. Moreover, the orphan drug status granted to ALN-TTR02 by the US Food and Drug Administration (FDA) ensures seven years of marketing exclusivity once the candidate is approved.

Alnylam, a biopharmaceutical company, presently carries a Zacks Rank #2 (Buy). However, biopharmaceutical stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) and Santarus, Inc. look better positioned carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%